Impax Laboratories (Nasdaq: IPXL) is expected to report Q3 earnings on Oct. 30. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Impax Laboratories's revenues will increase 34.7% and EPS will grow 60.0%.

The average estimate for revenue is $161.4 million. On the bottom line, the average EPS estimate is $0.48.

Revenue details
 Last quarter, Impax Laboratories logged revenue of $166.5 million. GAAP reported sales were 32% higher than the prior-year quarter's $125.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.60. GAAP EPS of $0.27 for Q2 were 42% higher than the prior-year quarter's $0.19 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 46.8%, 60 basis points worse than the prior-year quarter. Operating margin was 21.0%, 490 basis points better than the prior-year quarter. Net margin was 11.2%, 120 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $637.2 million. The average EPS estimate is $2.04.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 171 members out of 186 rating the stock outperform, and 15 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 43 give Impax Laboratories a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is outperform, with an average price target of $24.89.